@col69 early May is over in my book. We are now headed into mid May without a word.
Classic Starpharma and I was hoping our new CEO would display more integrity.
Suppose while JF has still got her hands in the till her bad habits are continuing to rub off.
Regarding the webinar (which has been watered down from an actual shareholders meeting) imo the focus should be squarely on the 3 Dep drugs before any other business. This has been the company's primary strategy for 20 odd years and we have a right to be properly informed.
I'm over the "continuing commercial discussions" diatribe. Are we likely to see a deal or is it about to disappear into the ether with Eli Lily, Chase Sun, AZ, Dep Gemcitibane, SPL7013 for Viral Conjunctivitis, the Indian Viraleze deal which was finalising distribution arrangements several years ago, The Viraleze distributors in NZ, Malaysia, Indonesia, the Middle East etc.
SPL Price at posting:
12.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)